2025-01-22 10:48:51 :
Rossari Biotech Q3 2025 Results: Rossari Biotech reported its Q3 results on January 21, 2025, revealing mixed results for the quarter. The company’s revenue increased by 10.56% year-on-year, reaching $512.73 Crores. However, profits fell by 7.82% year-on-year, totaling $31.7 Crores.
Compared to the previous quarter, Rosari’s revenue increased by 2.89%, while profits fell by 10.27%. The reason for the decline in profits was the increase in operating costs, with sales, general and administrative expenses increasing by 9.61% month-on-month and 37.06% year-on-year.
Operating income also faced challenges, falling 8.53% month-on-month and 4.38% year-on-year. Third quarter earnings per share (EPS) reported at $5.72, a year-on-year decrease of 7.89%.
Rosari Biotechnology Inc. returned -3.55% last week, -0.42% over the past six months, and 3.24% year-to-date.
Currently, Rosari Biotech has a market capitalization of $4441.79 Crores, a new 52-week high $972.7 and minimum $656.95.
Out of the five analysts covering the company as of January 22, 2025, one analyst has assigned a Hold rating and four recommend a Strong Buy. As of the same date, the consensus recommendation for Rosari Biotech was a Strong Buy.
Rosari Biotech Finance
| period | Q3 (FY2025) | Q2 (FY25) | month-on-month growth | Q3 (FY2024) | year-on-year growth |
|---|---|---|---|---|---|
| total revenue | 512.73 | 498.35 | +2.89% | 463.77 | +10.56% |
| Total Selling/General/Administrative Expenses | 35.69 | 32.56 | +9.61% | 26.04 | +37.06% |
| Depreciation/Amortization | 18.32 | 15.16 | +20.84% | 15.09 | +21.4% |
| total operating expenses | 466.29 | 447.57 | +4.18% | 415.19 | +12.31% |
| operating income | 46.45 | 50.78 | -8.53% | 48.58 | -4.38% |
| net income before tax | 42.38 | 48.11 | -11.91% | 47.78 | -11.3% |
| net income | 31.7 | 35.33 | -10.27% | 34.39 | -7.82% |
| Diluted normalized earnings per share | 5.72 | 6.38 | -10.34% | 6.21 | -7.89% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
Follow us On Social Media Twitter/X
